EMA Withdrawn: IntronA (interferon alfa-2b) — Merck Sharp & Dohme B.V.

View source ↗

Summary

The European Medicines Agency has withdrawn IntronA (interferon alfa-2b) from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Tumor
• Leukemia Hairy Cell
• Leukemia Myelogenous Chronic Bcr-abl Positive
• Lymphoma Follicular
• Melanoma
• Multiple Myeloma
• Viral Hepatitis

Drugs mentioned

• IntronA (interferon alfa-2b)

Snippet

Status: Withdrawn. Therapeutic area: Carcinoid Tumor;Leukemia, Hairy Cell;Lymphoma, Follicular;Hepatitis B, Chronic;Hepatitis C, Chronic;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Melanoma;Multiple Myeloma. MAH: Merck Sharp & Dohme B.V.. Decision date: 10/06/2021